These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23580146)

  • 1. Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy.
    Hornstrup LS; Frikke-Schmidt R; Nordestgaard BG; Tybjærg-Hansen A
    Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1441-7. PubMed ID: 23580146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transthyretin-stabilising mutation T119M is not associated with protection against vascular disease or death in the UK Biobank.
    Parker MM; Ticau S; Butler J; Erbe D; Merkel M; Aldinc E; Hinkle G; Nioi P
    Amyloid; 2020 Sep; 27(3):184-190. PubMed ID: 32425064
    [No Abstract]   [Full Text] [Related]  

  • 3. Promotor polymorphisms in leukotriene C4 synthase and risk of ischemic cerebrovascular disease.
    Freiberg JJ; Tybjaerg-Hansen A; Sillesen H; Jensen GB; Nordestgaard BG
    Arterioscler Thromb Vasc Biol; 2008 May; 28(5):990-6. PubMed ID: 18276912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119M.
    Almeida MR; Alves IL; Terazaki H; Ando Y; Saraiva MJ
    Biochem Biophys Res Commun; 2000 Apr; 270(3):1024-8. PubMed ID: 10772944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Low Plasma Transthyretin Concentration With Risk of Heart Failure in the General Population.
    Greve AM; Christoffersen M; Frikke-Schmidt R; Nordestgaard BG; Tybjærg-Hansen A
    JAMA Cardiol; 2021 Mar; 6(3):258-266. PubMed ID: 33237279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects.
    Johannsen TH; Frikke-Schmidt R; Schou J; Nordestgaard BG; Tybjærg-Hansen A
    J Am Coll Cardiol; 2012 Nov; 60(20):2041-8. PubMed ID: 23083790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression.
    Sekijima Y; Dendle MT; Wiseman RL; White JT; D'Haeze W; Kelly JW
    Amyloid; 2006 Jun; 13(2):57-66. PubMed ID: 16911959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variation in liver X receptor alpha and risk of ischemic vascular disease in the general population.
    Stender S; Frikke-Schmidt R; Anestis A; Kardassis D; Sethi AA; Nordestgaard BG; Tybjærg-Hansen A
    Arterioscler Thromb Vasc Biol; 2011 Dec; 31(12):2990-6. PubMed ID: 21903943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52,000 individuals.
    Kaur-Knudsen D; Bojesen SE; Nordestgaard BG
    Pharmacogenomics J; 2009 Oct; 9(5):327-32. PubMed ID: 19652664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrin beta3 Leu33Pro polymorphism and risk of hip fracture: 25 years follow-up of 9233 adults from the general population.
    Tofteng CL; Bach-Mortensen P; Bojesen SE; Tybjaerg-Hansen A; Hyldstrup L; Nordestgaard BG
    Pharmacogenet Genomics; 2007 Jan; 17(1):85-91. PubMed ID: 17264806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease.
    Soares ML; Coelho T; Sousa A; Batalov S; Conceição I; Sales-Luís ML; Ritchie MD; Williams SM; Nievergelt CM; Schork NJ; Saraiva MJ; Buxbaum JN
    Hum Mol Genet; 2005 Feb; 14(4):543-53. PubMed ID: 15649951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hereditary hemochromatosis genotypes and risk of ischemic stroke.
    Ellervik C; Tybjaerg-Hansen A; Appleyard M; Sillesen H; Boysen G; Nordestgaard BG
    Neurology; 2007 Mar; 68(13):1025-31. PubMed ID: 17389307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between interleukin-6 levels and first-ever cerebrovascular events in patients with vascular risk factors.
    Miwa K; Tanaka M; Okazaki S; Furukado S; Sakaguchi M; Mochizuki H; Kitagawa K
    Arterioscler Thromb Vasc Biol; 2013 Feb; 33(2):400-5. PubMed ID: 23175672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterozygosity for R1141X in ABCC6 and risk of ischemic vascular disease.
    Hornstrup LS; Tybjærg-Hansen A; Haase CL; Nordestgaard BG; Sillesen H; Grande P; Frikke-Schmidt R
    Circ Cardiovasc Genet; 2011 Oct; 4(5):534-41. PubMed ID: 21831958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and clinical characterization of prealbuminCHICAGO: an apparently benign variant of serum prealbumin (transthyretin) discovered with high-resolution two-dimensional electrophoresis.
    Harrison HH; Gordon ED; Nichols WC; Benson MD
    Am J Med Genet; 1991 Jun; 39(4):442-52. PubMed ID: 1877623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial haplogroups: ischemic cardiovascular disease, other diseases, mortality, and longevity in the general population.
    Benn M; Schwartz M; Nordestgaard BG; Tybjaerg-Hansen A
    Circulation; 2008 May; 117(19):2492-501. PubMed ID: 18458168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity.
    Arking DE; Atzmon G; Arking A; Barzilai N; Dietz HC
    Circ Res; 2005 Mar; 96(4):412-8. PubMed ID: 15677572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transthyretin: no association between serum levels or gene variants and schizophrenia.
    Ruano D; Macedo A; Soares MJ; Valente J; Azevedo MH; Hutz MH; Gama CS; Lobato MI; Belmonte-de-Abreu P; Goodman AB; Pato C; Saraiva MJ; Heutink P; Palha JA
    J Psychiatr Res; 2007 Oct; 41(8):667-72. PubMed ID: 16716350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease.
    Juul K; Tybjaerg-Hansen A; Marklund S; Lange P; Nordestgaard BG
    Am J Respir Crit Care Med; 2006 Apr; 173(8):858-64. PubMed ID: 16399992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [C-reactive protein and risk of ischaemic vascular and cerebrovascular disease--secondary publication].
    Zacho J; Tybjaerg-Hansen A; Jensen JS; Grande P; Sillesen H; Nordestgaard BG
    Ugeskr Laeger; 2009 May; 171(21):1751-5. PubMed ID: 19492468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.